[The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
作者信息
Sjölin-Forsberg Gunilla, Lindeskog Bengt, Lundqvist Kristina Magnusson, Feltelius Nils, Alvan Gunnar
出版信息
Lakartidningen. 2007;104(16):1226-9.
PMID:17536352
Abstract
摘要
相似文献
1
[The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
Lakartidningen. 2007;104(16):1226-9.
2
3
[Classification and profile of adverse drug effects].[药物不良反应的分类与概况]
Bull Soc Belge Ophtalmol. 2007(304):15-6.
4
Points to consider: the roles of surveillance and epidemiology in advancing drug safety.需考虑的要点：监测与流行病学在推进药物安全方面的作用。
Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):665-7. doi: 10.1002/pds.1072.
5
Improving pharmacovigilance in Europe.提高欧洲的药物警戒水平。
BMJ. 2010 Apr 12;340:c1694. doi: 10.1136/bmj.c1694.
6
European commission consultation on pharmacovigilance.欧盟委员会关于药物警戒的咨询。
Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):108-9. doi: 10.1002/pds.1526.
7
Accelerating statistical research in drug safety.
Pharmacoepidemiol Drug Saf. 2006 Sep;15(9):687-8. doi: 10.1002/pds.1267.
8
[Increased significance of adverse effects of drugs--a threat to the industry].
Lakartidningen. 2004 Dec 9;101(50):4134-6.
9
[The battle against adverse effects of drugs goes on. Comments to a survey].[对抗药物不良反应的斗争仍在继续。对一项调查的评论]
Lakartidningen. 2004 Mar 11;101(11):1016-8.
10
Beware of new drugs, study suggests.研究表明，谨防新药。
Rep Med Guidel Outcomes Res. 2002 May 17;13(10):1-2, 5.
Zotero 插件